PL
Patrick Lin
Chief Business - Strategy Off

Patrick Lin insider trades: Processa Pharmaceuticals (PCSA) stock purchases

Chief Business - Strategy Off, Processa Pharmaceuticals Last trade Jun 30, 2026 35 Form 4 filings
$0
Sold, last 12 months
0 sales
$20K
Bought, last 12 months
5 buys
15
Open-market trades
since 2020
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Patrick reports to the SEC

Open-market buys and sales

15 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 30, 2026PCSA↑ Buy$4K
Jun 15, 2026PCSA↑ Buy$4K
May 15, 2026PCSA↑ Buy$4K
Apr 15, 2026PCSA↑ Buy$4K
Mar 31, 2026PCSA↑ Buy$4K
Jan 27, 2025PCSA↑ Buy$35K
Feb 1, 2024PCSA↑ Buy$10K
May 17, 2022PCSA↑ Buy$3K
Apr 7, 2022PCSA↑ Buy$7K
Dec 14, 2021PCSA↑ Buy$12K
Dec 14, 2021PCSA↑ Buy$12K
Dec 3, 2021PCSA↑ Buy$17K
Aug 26, 2021PCSA↑ Buy$24K
Jun 21, 2021PCSA↑ Buy$13K
Oct 1, 2020PCSA↑ Buy$66K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other PCSA insiders

Open-market trades in the last 12 months

About Patrick Lin's insider trades

Patrick Lin is Chief Business - Strategy Off at Processa Pharmaceuticals (PCSA). Since Oct 1, 2020, Patrick has reported 15 open-market purchases worth $218K and no sales on SEC Form 4. In the last 12 months: 5 buys ($20K).

Their filings also include grants and awards (16 filings), option exercises (5 filings), shares withheld for taxes (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PCSA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.